Neoadjuvant bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: Results from a phase II trial (AVANTHER)

被引：0
|
作者：
Fernandez Abad, Maria
Calvo, Isabel
Martinez, Noelia
Herrero, Mercedes
Quijano, Yolanda
Duran, Hipolito
Garcia Aranda, Mariola
Suarez, Ana
Lopez-Rios, Fernando
Perez, Diego
Perea, Sofia
Hidalgo, Manuel
Garca-Estevez, Laura
机构：
[1] Ctr Integral Oncol Clara Campal, Madrid, Spain
[2] Hosp Ramon & Cajal, E-28034 Madrid, Spain
[3] Hosp Costa Sol, Marbella, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
602
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Final results of neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER)
    Fernandez, M.
    Calvo, I.
    Martinez, N.
    Herrero, M.
    Quijano, Y.
    Duran, H.
    Garcia-Aranda, M.
    Suarez, A.
    -Rios, F. Lopez
    Perez, D.
    Perea, S.
    Hidalgo, M.
    Garcia-Estevez, L.
    CANCER RESEARCH, 2012, 72
  • [2] Neoadjuvant trial of bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: A phase II trial (AVANTHER). Analysis of biomarkers
    Fernandez, M.
    Martinez, N.
    Calvo, I.
    Garcia, E.
    Ugidos, L.
    Herrero, M.
    Quijano, Y.
    Duran, H.
    Garcia, M.
    Suarez, A.
    Lopez-Rios, F.
    Perez, D.
    Perea, S.
    Hidalgo, M.
    Garcia-Estevez, L.
    CANCER RESEARCH, 2013, 73
  • [3] A phase II trial of neoadjuvant epirubicin/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer
    Kodera, A.
    Hirano, A.
    Inoue, H.
    Ogura, K.
    Hattori, A.
    Sakaguchi, S.
    Yukawa, H.
    Matsuoka, A.
    Tanaka, N.
    Kamimura, M.
    Jibiki, N.
    Fujibayasi, M.
    Naritaka, Y.
    Shimizu, T.
    CANCER RESEARCH, 2017, 77
  • [4] Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
    Ricciardi, Giuseppina Rosaria Rita
    Franchina, Tindara
    Russo, Alessandro
    Schifano, Silvia
    Ferraro, Giuseppa
    Adamo, Vincenzo
    ONCOTARGETS AND THERAPY, 2016, 9 : 4351 - 4355
  • [5] Phase II Trial of Neoadjuvant Pegylated Liposomal Doxorubicin with Paclitaxel and Trastuzumab in Patients with Operable Her2-Positive Breast Cancer
    Hyams, D. M.
    Leichman, G. C.
    Klein, P.
    Rietchsel, P.
    Levine, E. G.
    Gebski, V. J.
    Kelley, M. A.
    CANCER RESEARCH, 2009, 69 (24) : 570S - 570S
  • [6] A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Takahashi, M.
    Hayashida, T.
    Sakata, M.
    Hirose, S.
    Kitagawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
    Vieira, Claudia
    Borges, Andreia
    Pereira, Filipa F.
    Antunes, Pedro
    Redondo, Patricia
    Antunes, Luis
    Lopes, Jose M.
    Goncalves, Francisco R.
    Borges, Marina
    Bento, Maria J.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2023, 6 (01) : 1 - 9
  • [8] Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study
    Untch, Michael
    Rezai, Mahdi
    Loibl, Sibylle
    Fasching, Peter A.
    Huober, Jens
    Tesch, Hans
    Bauerfeind, Ingo
    Hilfrich, Joern
    Eidtmann, Holger
    Gerber, Bernd
    Hanusch, Claus
    Kuehn, Thorsten
    du Bois, Andreas
    Blohmer, Jens-Uwe
    Thomssen, Christoph
    Costa, Serban Dan
    Jackisch, Christian
    Kaufmann, Manfred
    Mehta, Keyur
    von Minckwitz, Gunter
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : 2024 - 2031
  • [9] Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer.
    Carey, Lisa A.
    Berry, Donald A.
    Ollila, David
    Harris, Lyndsay
    Krop, Ian E.
    Weckstein, Douglas
    Henry, Norah Lynn
    Anders, Carey K.
    Cirrincione, Constance
    Winer, Eric P.
    Perou, Charles M.
    Hudis, Clifford
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer.
    Jinno, H.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
12345